According to a report published by Grand View Research, Inc.; the vaccine contract manufacturing market is expected to reach a valuation of around USD 4.0 billion by 2025.
Increasing demand for vaccine development from the private and government sectors in developed and developing countries can boost the market growth during the forecast period (2014 to 2025).
Huge investments in equipment, skilled labor, and several facilities, in countries need to increase or localize inoculation supply are positively boost the demand for these services in the coming years. Companies are increasingly choosing for these services due to involvement of high capital requirement and associated complexity in the production process. In addition, many low-resources countries with inadequate skilled labor or equipment are expected to complete their demand with the help of these services. These contract services offer cost-saving benefits to their clients and help save time in operations and management of a production and research facility. Increasing awareness regarding benefits of vaccination in developing countries has led routine immunization programs and development of new inoculations. Rising shift towards the cell-based vaccine production has encouraged many contract vendors to improve their production strategies for manufacturing cell culture inoculations. This is expected to be the crucial factor for the market. Increasing number of pipeline products has augmented the demand for subcontracting services. Small as well as established or large firms consider these services as a cost-effective approach to improve product pipeline and increase their share in biopharmaceutical industry Therefore, strong pipeline and lack of capacity are likely to boost the demand for these services in the coming years.
Full Research Report On Vaccine Contract Manufacturing Market Analysis: https://www.grandviewresearch.com/industry-analysis/vaccine-contract-manufacturing-market
Still, some established companies think outsourcing dicey due to restricted management control and loss of strategic control. Thus, established pharma companies opt for inhouse manufacturing operations, which is expected to restrain the market growth over the forecast period.
Worldwide vaccine contract manufacturing market can be segmented on the basis of type, workflow, application, and region. Based on type, the market can be bifurcated into attenuated vaccine, inactivated vaccine, subunit vaccines, toxoid vaccines, and DNA vaccines. In 2016, the inactivated vaccines segment estimated for important as these types are safer and comparatively more stable than other types. The attenuated vaccines occupied the large share due to their ability to produce strong cellular and antibody responses. The large number of products approved for oral or intranasal administration are attenuated, which is the major driving factor for the segment. These type offer lifetime immunities with one or two doses. The DNA vaccines segment are likely to show lucrative growth in the coming years due their effectiveness in several illness. The subunit segment is likely to show steady growth during the forecast period due to constant research for the development of recombinant subunit vaccine against Hepatitis C virus.
View More Reports Of This Category By Grand View Research At: https://www.grandviewresearch.com/industry/pharmaceuticals
As per workflow, the market can be classified into downstream and upstream. In 2016, the downstream segment dominated the market. However, the upstream process is anticipated to grow rapidly due to technological developments in bioprocessing techniques and single-use technologies in upstream processing. On the basis of application, the market can be categorized into human use and veterinary.
Geographically, the market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has been dominating the market on account of extensive manufacturing of vaccines and rise in number of biopharmaceutical facilities in the region. Supportive regulations in laws regarding development of vaccines and other biologics in this region especially in the U.S. and Canada are anticipated to create positive drive the growth of contract research organizations (CROs) and contract manufacturing organizations (CMOs).
Asia Pacific is expected to be the fastest growing markets for inoculations manufacturing and research and development. This can be associated with factors such as refining infrastructure in developing countries, existence of several potential study subjects, and new regulatory changes in this region.
Key companies operating in the market include FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; Cytovance Biologics; Catalent, Inc.; Ajinomoto Althea, Inc.; and Paragon Bioservices, Inc.
Explore the BI enabled intuitive market research database, The Grand Library, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States